![]() |
|
|
Vol. 300, Issue 2, 567-576, February 2002
B/Nuclear Factor-
B-Sensitive Pathway in Alveolar
Epithelial Cells
Neuroscience Research Laboratory, Department of Anesthesia and Perioperative Care, University of California Medical Center, San Francisco, California (J.J.H.); Oxygen Signaling Group, Center for Research into Human Development, Tayside Institute of Child Health, Faculty of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom (S.C.L.); Department of Neonatal Medicine, Westmead Hospital and New Children's Hospital Neonatal Service, University of Sydney, New South Wales, Sydney, Australia (W.O.T.-M.); and Departments of Clinical Immunology and Microbiology and Neonatology, Jagiellonian University Medical College, Cracow, Poland (M.Z., D.K., R.L.)
| |
Abstract |
|---|
|
|
|---|
In this report we investigated the immunopharmacological role of
selective and nonselective phosphodiesterase (PDE) inhibition in
regulating the inhibitory-
B (I
B-
)/nuclear factor-
B
(NF-
B) signaling transduction pathway. In fetal alveolar type II
epithelial cells, PDE blockade at the level of the diverging cAMP/cGMP
pathways differentially regulated the phosphorylation and degradation
of I
B-
, the major cytosolic inhibitor of NF-
B. Whereas
selective inhibition of PDEs 1, 3, and 4, by the action of
8-methoxymethyl-3-isobutyl-1-methylxanthine, amrinone, and
rolipram, respectively, exhibited a tendency to augment the
translocation of NF-
B1 (p50), RelA (p65), RelB (p68), and c-Rel (p75), selective blockade of PDE 5, 6, and 9, by the action of
4-{[3',4'-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline and
zaprinast, attenuated lipopolysaccharide-endotoxin (LPS)-mediated NF-
B translocation. Pentoxifylline, a nonspecific PDE inhibitor, reversed the excitatory effect of LPS on NF-
B subunit nuclear localization, in a dose-dependent manner. Furthermore, analysis of
NF-
B activation under the same conditions revealed a biphasic effect
mediated by LPS. PDEs 1, 3, and 4 inhibition was associated with
up-regulating NF-
B transcriptional activity. In contrast, blockading
the activity of PDEs 5, 6, and 9 negatively attenuated LPS-mediated
NF-
B activation, similar to the effect
of 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione (pentoxifylline).
These results indicate that selective and nonselective interference
with the control of the dynamic equilibrium of cyclic nucleotides via
PDE isoenzyme regulation represents an immunoregulatory mechanism that
requires the differential, biphasic targeting of the I
B-
/NF-
B pathway.
| |
Introduction |
|---|
|
|
|---|
Although
the transcription factor nuclear factor-
B (NF-
B) has been
originally recognized in regulating gene expression in B-cell
lymphocytes (Sen and Baltimore, 1986
), subsequent investigations have
demonstrated that it is one member of a ubiquitously expressed family
of Rel-related transcription factors that serve as critical regulators of many genes, including those of proinflammatory cytokines (Siebenlist et al., 1994
; Baldwin, 1996
, 2001
; Haddad et al., 2001b
).
The translocation and activation of NF-
B in response to various
stimuli are sequentially organized at the molecular level. In its
inactive state, the heterodimeric NF-
B, which is mainly composed of
two subunits, p50 (NF-
B1) and p65 (RelA), is
present in the cytoplasm associated with its inhibitory protein, I
B
(Siebenlist et al., 1994
; Baldwin, 1996
). Upon stimulation, such as
with cytokines and lipopolysaccharide-endotoxin (LPS), derived from the
cell wall of Gram-negative bacteria, I
B-
, the major cytosolic
inhibitor of NF-
B (Baldwin, 1996
; Haddad et al., 2001b
), undergoes
phosphorylation on serine/threonine residues, ubiquitination, and
subsequent proteolytic degradation, thereby unmasking the nuclear
localization signal (NLS) on p65 and allowing nuclear translocation of
the complex. This sequential propagation of signaling ultimately
results in the release of NF-
B subunits from I
B-
inhibitor,
allowing translocation and promotion of gene transcription.
Phosphodiesterases (PDEs), a family of isoenzymes involved in
regulating the dynamic equilibrium of cyclic nucleotides (cAMP/cGMP) (Pagani et al., 1992
; Bolger et al., 1993
; Tsuboi et al., 1996
; Ekholm
et al., 1997
; Perry and Higgs, 1998
; Essayan, 1999
), have been recently
implicated in regulating the I
B-
/NF-
B signaling pathway and
other transcription factors (Montminy, 1997
). For instance, it was
reported that the transcriptional activity of NF-
B was regulated by
the I
B-associated catalytic subunit of protein kinase A (PKAc) in a
cAMP-independent mechanism (Zhong et al., 1997
). Furthermore, Wang et
al. (1997)
observed that c-Rel (p75), one of the members of the
Rel family, formed a selective target of pentoxifylline, a
nonspecific PDE inhibitor, in mediating the inhibition of T-lymphocyte
activation. In addition, pentoxifylline blockaded reactive oxygen
species-mediated regulation of NF-
B independently of the
phosphodiesterase inhibitory activity (Lee et al., 1997
). Relatively
recently, a correlation of note was observed between the suppression of
proinflammatory cytokine production and the inhibition of NF-
B/NFAT
signaling pathway mediated by PDE type 4 isozymes (Navarro et al.,
1998
). Moreover, Tomita et al. (1999)
reported a novel role for
dexamethasone and theophylline, another nonspecific inhibitor of PDE,
in regulating NF-
B translocation/activation and cytokine expression.
In addition, selective inhibition of PDE 3 attenuated the activation of
NF-
B and subsequently blockaded the downstream cytokine signaling
pathway (Matsumori et al., 2000
). However, the immunopharmacological
role that selective and nonselective inhibition of PDE isoenzymes plays
in regulating the nuclear translocation and activation of NF-
B is
not well characterized and thereby remains to be identified in the
alveolar epithelium.
Therefore, the aim of the present investigation targeted a dual
analytical assessment of PDE inhibition. First, a determination was
made of the interference of selective phosphodiesterase isoenzymes in
regulating the phosphorylation, degradation, and accumulation of
I
B-
within the cytosolic compartment; and second, an evaluation was made of the role that those isoenzymes play in determining the
nuclear translocation of selective NF-
B Rel subunits,
thereby interfering with the activation of NF-
B, a transcriptional
activity involved in regulating genes encoding cytokines and the
progression and evolution of inflammation.
| |
Materials and Methods |
|---|
|
|
|---|
All experimental procedures involving the use of live animals were reviewed and approved under the Animals Act legislation, 1986 (United Kingdom). Unless indicated otherwise, chemicals/reagents of the highest analytical grade were obtained from Sigma-Aldrich (Dorset, England) and Calbiochem (Nottingham, UK).
Primary Cultures of Alveolar Epithelia.
Fetal alveolar type
II epithelial cells were isolated from lungs of rat fetuses on
gestation day 19, essentially as described elsewhere (Haddad and Land,
2000a
,b
; Haddad et al., 2000
, 2001a
,b
,c
).
LPS Exposure and Assessment of the Effect of
Phosphodiesterase Inhibitors (PDEIs) on NF-
B
Translocation/Activation.
The signaling mechanism mediating the
effect of selective and nonselective inhibition of PDEs in regulating
NF-
B translocation and activation in the alveolar epithelium is not
well characterized. Accordingly, we designed a series of experiments to
span NF-
B translocation/activation in response to LPS and PDEI
treatment. Cells were challenged with LPS (10 µg/ml) independently or
in the presence of various PDEIs. Subcellular cytosolic/nuclear
extracts (24 h) were subsequently prepared, followed by Western
analysis and electrophoretic mobility gel shift assay, essentially as
described previously (Haddad and Land, 2000a
; Haddad et al., 2000
).
Briefly, cytosolic/nuclear extracts were prepared from monolayer
filters washed twice in 5 ml of ice-cold, pre-equilibrated
phosphate-buffered saline and cells (1-2 × 107) were collected and centrifuged at
420g for 5 min at 4°C. Nuclei were released by
resuspending the pellet in 250 µl of buffer A containing 10 mM
Tris-HCl, pH 7.8, 10 mM KCl, 2.5 mM
NaH2PO4, 1.5 mM
MgCl2, 1 mM
Na3VO4, 0.5 mM
dithiothreitol, 0.4 mM 4-(2-aminoethyl)benzenesulfonyl fluoride-HCl,
and 2 µg/ml each of leupeptin, pepstatin A, and aprotinin. The
suspension was left in ice for 10 min followed by a 45-s homogenization
at a moderate speed. Nuclei were collected by centrifuging the slurry
at 4500g for 5 min at 4°C and resuspending in 100 µl of
buffer B [buffer A adjusted to 20 mM Tris-HCl, pH 7.8, 420 mM KCl,
20% (v/v) glycerol]. The supernatants thus obtained were termed
cytosolic extracts. The nuclei were then lysed at 4°C for 30 min with
gentle agitation, the debris cleared by centrifugation at
10,000g for an additional 30 min at 4°C, and the
supernatants, termed nuclear extracts, were frozen in liquid nitrogen
and stored at
70°C until used. In all cases, protein contents were
determined by the Bradford method by using bovine serum albumin as a
standard (Haddad and Land, 2000a
).
B-
(H-4),
IgG2b anti-pI
B-
(B-9), rabbit polyclonal IgG anti-p50 (NLS), anti-p52 (K-27), anti-p65 (RelA; A),
anti-p68 (RelB; C-19), and anti-p75 (c-Rel; N) (Santa Cruz Biotechnology, Wiltshire, UK) antibodies were used for primary detection. Anti-rabbit Ig-biotinylated antibody (Amersham plc, Little
Chalfont, Buckinghamshire, UK) was used for secondary detection followed by the addition of streptavidin-horseradish peroxidase conjugate and visualized on film by chemiluminescence.
-Actin standard was used as an internal reference for semiquantitative loading
in parallel lanes for each variable. Western blots were scanned by NIH
MagiScanII and subsequently quantitated by UN-Scan-IT automated
digitizing system (version 5.1; 32-bit), and the ratio of the density
of the band to that of
-actin was subsequently performed.
Custom deoxyoligonucleotide probe sequences were purchased from Genosys
(Cambridge, UK): NF-
B, 5'-AGTTGAGGGGACTTTCCCAGGC-3' (binding sequence underlined). Gel-purified double-stranded DNA was
end-labeled with [
-32P]ATP (PerkinElmer Life
Sciences Ltd., Cambridge, UK). Identical amounts of radioactive
probe (1-2 × 104 counts/min) were added to
binding reactions containing 1 to 5 µg of fetal alveolar type II
nuclear extracts in a final volume of 40 µl in DNA binding buffer (20 mM HEPES, pH 7.9; 1 mM MgCl2; 4% Ficoll).
Reaction mixtures were incubated for 30 min at 25°C before separating
on nondenaturing 4% polyacrylamide gels at room temperature and
subjected to electrophoresis with 1:10 5× Tris-borate-EDTA buffer. A
nonspecific competitive polydeoxyinosinic-deoxycytidylic acid
[poly(dI-dC)] (Amersham plc) was added to reaction mixtures after
addition of labeled probe. Gels were transferred to ion-exchange chromatography paper, vacuum dried, and then electronically visualized on a Packard Instant PhosphorImager (Packard BioScience Ltd., Berkshire, UK). Specific quantitation of the corresponding DNA gel shift bands was performed with phosphorimaging (Haddad and Land,
2000aStatistical Analysis and Data Presentation.
Data are the
means and the error bars the S.E.M. of at least three independent cell
cultures. Statistical evaluation was performed by one-way analysis of
variance, followed by post hoc Tukey's test, and the a priori level of
significance at 95% confidence level was considered at
P
0.05.
| |
Results |
|---|
|
|
|---|
Involvement of Selective Phosphodiesterase Isoenzymes in Regulating
I
B-
Signaling.
In a previous study, we have reported a
detailed account of I
B-
signaling in response to exogenous LPS,
derived from Escherichia coli (Haddad et al., 2001b
). As
shown in Fig. 1A, LPS (10 µg/ml; 24 h) mediated the degradation of I
B-
within the cytosolic
compartment. Coincubation of cells with LPS and PDEIs differentially
regulated LPS-mediated degradation of I
B-
(Fig. 1). The effect of
8-methoxymethyl-IBMX (PDEI1) on I
B-
abundance is shown in
Fig. 1A. 8-Methoxymethyl-IBMX had no effect on LPS-dependent
degradation of I
B-
at 1 and 10 µM, but reversed the effect of
LPS at 100 µM, thereby allowing its cytosolic accumulation (Fig.
1A). The effect of 5-amino-(3,4'-bipyridin)-6[1H]-one (amrinone; PDEI3) on I
B-
abundance is displayed in Fig. 1A. In
contrast to PDEI1, amrinone reversed the degradation effect of LPS at
all doses used in this study, thereby allowing the accumulation of
I
B-
in the cytosol (Fig. 1A). In comparison with either PDEI1 and
3,4-[3-(cyclopentyloxy)-4-methoxy-phenyl]-2-pyrrolidinone (rolipram)
(PDEI4) partially reversed the effect of LPS on I
B-
abundance,
allowing its accumulation but to a lesser extent than the effect of
amrinone (Fig. 1A). The effect of MBMQ (PDEI5) on I
B-
abundance
is displayed in Fig. 1B. MBMQ did not affect or reverse the effect of
LPS at all doses (Fig. 1B). The role of 1,4- dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimi dine-7-one
(zaprinast) (PDEI5/6/9) in regulating LPS-mediated I
B-
abundance
is shown in Fig. 1B. Zaprinast partially reduced LPS-induced I
B-
degradation at 100 µM (Fig. 1B). The effect of pentoxifylline
(nonselective PDEI) on I
B-
abundance is displayed in Fig. 1B.
Pentoxifylline partially restored I
B-
abundance, especially at 1 and 10 µM, but not at 100 µM (Fig. 1B). Histogram analysis of the
effect of selective PDE inhibition on I
B-
abundance is shown in
Fig. 2A. Analysis of the half-maximal
(50%) excitatory concentration (EC50) of
selective and nonselective phosphodiesterase inhibitors on I
B-
abundance/degradation regulated by LPS (10 µg/ml; 24 h) is given
in Table 1.
|
|
|
B-
, the major cytosolic inhibitor of NF-
B (Baldwin, 2001
B-
abundance within the cytosolic compartment, we aimed at investigating the role
that these isoenzymes play in regulating I
B-
phosphorylation. As
shown in Fig. 1C, 8-methoxymethyl-IBMX up-regulated LPS-mediated phosphorylation of I
B-
at 1 µM, but not at higher
concentrations, whose effects were similar to that of LPS alone (Fig.
1C). The effect of amrinone on I
B-
phosphorylation is displayed
in Fig. 1C. Amrinone up-regulated LPS-dependent phosphorylation of
I
B-
at the highest dose used (100 µM), but not at lower doses
(Fig. 1C). Rolipram suppressed LPS-dependent phosphorylation of
I
B-
in a dose-independent manner (Fig. 1C). The effect of MBMQ on I
B-
phosphorylation is shown in Fig. 1D. MBMQ up-regulated
I
B-
phosphorylation at 100 µM, with similar effects to LPS at
the lower range of the dose-response curve (Fig. 1D). The role of zaprinast in regulating LPS-mediated I
B-
phosphorylation is displayed in Fig. 1D. Zaprinast up-regulated LPS-dependent
phosphorylation of I
B-
at all doses (Fig. 1D). The effect of
pentoxifylline on I
B-
phosphorylation is shown in Fig. 1D.
Pentoxifylline up-regulated LPS-mediated phosphorylation of I
B-
at the lowest dose (1 µM), but suppressed this effect at higher doses
(Fig. 1D). Histogram analysis of the effect of selective PDE inhibition
on I
B-
phosphorylation is shown in Fig. 2B. Analysis of the
half-maximal (50%) excitatory and inhibitory concentrations
(EC50/IC50) of selective
and nonselective phosphodiesterase inhibitors on I
B-
phosphorylation regulated by LPS (10 µg/ml; 24 h) is given in
Table 1.
Role of Phosphodiesterase Isoenzyme Inhibition in Regulating
Nuclear Translocation of Selective NF-
B Rel
Subunits.
Although LPS up-regulated the nuclear translocation of
NF-
B1 (p50), RelA (p65), RelB (p68), and c-Rel
(p75), it had no apparent effect on NF-
B2
(p52). 8-Methoxymethyl-IBMX had no inhibitory effect on LPS-mediated
translocation of p50, p65, p68, and p75, as shown in Fig.
3A. Similar to the effect of
8-methoxymethyl-IBMX, amrinone did not suppress LPS-mediated NF-
B
subunit translocation (Fig. 3B). As shown in Fig. 3C, rolipram did not
inhibit the translocation of NF-
B subunits. The housekeeping gene
protein product
-actin was used as an internal reference for
semiquantitative loading per lane (Fig. 3). The effect of MBMQ on
NF-
B subunit translocation is displayed in Fig.
4A, where there was an inhibitory effect at doses
1 µM (p50),
10 µM (p65),
1 µM (p68), and
10 µM
(p75). As shown in Fig. 4B, zaprinast blockaded LPS-mediated NF-
B
translocation of p50 (
10 µM), p65 (
1 µM), p68 (
1 µM), and
p75 (
10 µM). Pentoxifylline reduced the nuclear localization of p50
(
1 µM), p65 (
1 µM), p68 (
1 µM), and p75 (
1 µM), as
shown in Fig. 4C. The housekeeping gene protein product
-actin was
used as an internal reference for semiquantitative loading per lane
(Fig. 4). Analysis of the half-maximal (50%) excitatory and inhibitory
concentrations (EC50/IC50) of selective and nonselective phosphodiesterase inhibitors on NF-
B
subunit nuclear abundance regulated by LPS (10 µg/ml; 24 h) is
given in Table 2.
|
|
|
Effect of LPS on NF-
B DNA-Binding Activity: Time-Response
Analysis.
As shown in Fig. 5A,
incubation of epithelial cells with LPS (10 µg/ml) induced, in a
time-dependent manner, NF-
B activation. The nuclear activity of
NF-
B in response to LPS emerged significantly as early as 2 h
postaddition to monolayers, and continued to increase in an exponential
manner to maximize at 16- to 24-h time point (Fig. 5A). LPS-mediated
activity of NF-
B thereafter subsided beyond the 24-h time point,
although it remained significantly different from control (no LPS)
until 72 h, when it became insignificant at 96 h (Fig. 5A).
Histogram analysis of the corresponding gel-shifted bands is given in
Fig. 5B.
|
Effect of Phosphodiesterase Isoenzyme Inhibition on Nuclear
Activation of NF-
B.
In association with the differential
regulation of selective PDE inhibition on NF-
B subunit
translocation, PDEI revealed a novel role in regulating LPS-dependent
NF-
B activation by interfering with the binding to specific
B
moieties. As shown in Fig. 6A, 8-methoxymethyl-IBMX augmented LPS-induced NF-
B activation at 1 and
10 µM, with no apparent effect at 100 µM, the effect of which was
similar to LPS alone. Histogram analysis of the corresponding gel-shifted bands with 8-methoxymethyl-IBMX is given in Fig. 8A. Although amrinone at doses 1 and 10 µM behaved in a similar manner to
LPS, it up-regulated the effect of LPS at 100 µM (Fig. 6B). Histogram
analysis of the corresponding gel-shifted bands with amrinone is given
in Fig. 8B. Rolipram up-regulated LPS-mediated activation of NF-
B in
a dose-dependent manner (Fig. 6C). Histogram analysis of the
corresponding gel-shifted bands with rolipram is given in Fig. 8C. The
effect of MBMQ on NF-
B activation is displayed in Fig.
7A, where its inhibitory effects are
evident at doses
10 µM. Histogram analysis of the corresponding
gel-shifted bands with MBMQ is given in Fig.
8D. Similarly, zaprinast suppressed the
nuclear activation of NF-
B at doses
10 µM (Fig. 7B). Histogram analysis of the corresponding gel-shifted bands with zaprinast is given
in Fig. 8E. The effect of nonselective inhibition of PDE by
pentoxifylline is shown in Fig. 7C, where there was a dose-dependent inhibition. Histogram analysis of the corresponding gel-shifted bands
with pentoxifylline is shown in Fig. 8F. Analysis of the half-maximal
(50%) excitatory and inhibitory concentrations
(EC50/IC50) of selective
and nonselective phosphodiesterase inhibitors on NF-
B activation
regulated by LPS (10 µg/ml; 24 h) is given in Table 2.
|
|
|
| |
Discussion |
|---|
|
|
|---|
To accommodate an ever-changing microenvironment, cells adjust the
pattern of gene expression by adaptive regulation of a host of
transcription factors, which bind their respective cognate sites in the
regulatory elements of targeted genes (Makarov, 2000
; Baldwin, 2001
;
Tak and Firestein, 2001
; Yamamoto and Gaynor, 2001
). NF-
B
comprises the Rel family of inducible transcription factors that are key mediators in regulating the progression of the
inflammatory process (Yamamoto and Gaynor, 2001
). Therefore,
activation/regulation of the NF-
B/Rel transcription
family, via nuclear translocation of cytoplasmic entities and
complexes, plays a central role in the evolution of inflammation
through regulation of genes essentially involved in encoding
proinflammatory cytokines and other inflammatory mediators (Baldwin,
1996
, 2001
; Tak and Firestein, 2001
). The NF-
B/Rel family
includes five members: NF-
B1 (p50/p105 {p50 precursor}), NF-
B2 [p52/p100 (p52
precursor)], RelA (p65), RelB (p68) and c-Rel (p75) (Tak and
Firestein, 2001
). Despite the ability of most Rel members
(with the exception of p68) to homodimerize, as well as form
heterodimers, with each other, the most prevalent activated form of
NF-
B is the heterodimer p50-p65, which possesses the transactivity
domains necessary for gene regulation (Baldwin, 1996
; Makarov, 2000
;
Baldwin, 2001
). The NF-
B members contain a Rel homology
domain, which is responsible for dimer formation, nuclear
translocation, sequence-specific consensus DNA recognition, and
interaction with I
B, the cytosolic inhibitors of NF-
B (Baldwin 2001
; Tak and Firestein, 2001
). In unstimulated cells, NF-
B resides in the cytoplasm as an inactive NF-
B/I
B complex, a mechanism that
hinders the recognition of the NLS by the nuclear import machinery,
thereby retaining the NF-
B complex within the cytosol (Baldwin,
1996
, 2001
).
Signals emanating from membrane receptors, such as those for
interleukin-1 and tumor necrosis factor-
, activate members of the
mitogen-activated protein kinase kinase kinase-related family, including NF-
B inducing kinase and mitogen-activated protein kinase
kinase kinase1, both of which are involved in the
activation of I
B kinases, IKK1 and
IKK2, components of the IKK signalsome (Mercurio and Manning 1999
; Zandi et al., 1997
; Makarov, 2000
). These kinases phosphorylate members of the I
B family, including I
B-
, the major cytosolic inhibitor of NF-
B (Baldwin, 2001
; Haddad et al., 2001b
), at specific serines within their amino termini,
thereby leading to site-specific ubiquitination and degradation by the
proteasome. This sequential trajectory culminating in the inducible
degradation of I
B, which occurs through consecutive steps of
phosphorylation and ubiquitination, allows freeing of the NF-
B
complex, which translocates to the nucleus to bind specific
B
moieties and initiate gene transcription (Makarov, 2000
; Baldwin, 2001
). The immunoregulatory potential aimed at targeting the NF-
B signaling pathway, therefore, remains of particular interest. Because
NF-
B regulates host inflammatory and immune responses by increasing
the expression of specific genes and enzymes whose products contribute
to the pathogenesis of the inflammatory process (Makarov, 2000
;
Yamamoto and Gaynor, 2001
), selective modulation of this transcription
factor bears a typical therapeutic approach for the control and
regulation of inflammatory-associated diseases. Unfortunately, due to
convergence of more than one mechanism upon the onset and progression
of the inflammatory process, which regulates NF-
B signaling, it has
been extremely difficult to solely target this pathway without
affecting other cellular functions. Within this context, the
anti-inflammatory immunoregulatory role that phosphodiesterase
inhibition plays in regulating this pathway is not well understood or
characterized. Therefore, the major aim of the present investigation
was to shed light on the role that selective phosphodiesterases play in
regulating I
B-
/NF-
B signaling, thereby showing for the first
time that PDE inhibition differentially and dually regulates this
transduction pathway, bearing consequences for the therapeutic
treatment of inflammatory disease involving NF-
B and regulated by
the respiratory epithelium (Makarov, 2000
; Perkins, 2000
; Haddad et
al., 2001c
,d
; Yamamoto and Gaynor, 2001
).
Although the inflammatory signals mediated by LPS are recognized in
other systems and cell models, the role of LPS-mediated signaling and
its modulation by PDE isoenzymes in the alveolar epithelium is not well
characterized. Administration of LPS differentially regulated NF-
B
nuclear subunit translocation. Despite the observation that LPS has no
influence on the unit composition of p52, its stimulatory effect on
p50, p65, p68, and p75 is evidently prominent. Besides, the promoters
of genes encoding cytokines contain multiple cis-acting
motifs, including those that bind specific subunits (i.e., p50-p65) of
such transcription factors as NF-
B (Makarov, 2000
; Baldwin, 2001
;
Tak and Firestein, 2001
). Furthermore, the release of free
NF-
B upon extracellular stimulation due to I
B phosphorylation and
degradation, leads to DNA binding to initiate transcription of related
genes, including immunoreceptors, cytokines, and, interestingly, its
own inhibitor, I
B (Mercurio et al., 1997; Baldwin, 2001
; Haddad et
al., 2001b
). Two unique features of the NF-
B/I
B complex system
are deduced from its feedback regulation. The transcriptional
activation of NF-
B triggers the synthesis of I
B, and
NF-
B-activated transcription is maintained by continuous degradation
of I
B, which is sustained by an extracellular stimulus (Perkins,
2000
; Baldwin, 2001
; Haddad et al., 2001b
). Thus, the expression of
I
B parallels both NF-
B activity and the duration of the
activating extracellular stimulation, suggesting that this temporal
parallelism between I
B accumulation/degradation and an effective
external stimulation is a mechanism allowing dual, biphasic, regulation
of NF-
B within the alveolar space.
The novel interference of specific PDE isoenzyme inhibition in
regulating I
B-
phosphorylation/degradation, translocation of
selective NF-
B subunits, and the activation of this transcription factor remains of particular interest. Phosphodiesterase regulation of
I
B-
/NF-
B signaling pathway, however, is not well understood and remains to be elucidated. Coward et al. (1998)
, for example, reported that nonselective PDE inhibition possesses an
anti-inflammatory activity via suppression of NF-
B, bearing
consequences for the treatment of asthmatic patients. Furthermore,
pentoxifylline, a nonspecific methylxanthine-derived PDE inhibitor,
selectively targeted the c-rel (p75) NF-
B subunit, with variable and
inconsistent effect on RelA (p65), in the treatment of T-cell-dependent
diseases (Wang et al., 1997
), an observation correlating with another
investigation (Lee et al., 1997
). Alternatively, it was demonstrated
that the PKAc, but not the protein kinase A regulatory subunit, binds
I
B proteins and is associated with the NF-
B-I
B complex (Zhong
et al., 1997
). The authors concluded that PKAc interacts with I
B-
and I
B-
through sequences from the N terminus of the protein, and
that this interaction inhibits the catalytic activity of PKAc. Of note,
the observation that stimulation of cells with inducers of NF-
B
activity, such as LPS, agents that do not elevate intracellular cAMP,
led to degradation of I
B proteins and consequent activation of
I
B-bound PKAc (Zhong et al., 1997
). To the best of our knowledge, this is the first report that has given a detailed account of the role
of selective and nonselective PDE interference in regulating I
B-
/NF-
B signaling. The differential regulation of I
B-
phosphorylation, in particular, implicated a PDE-sensitive upstream
kinase. However, from the present data alone it cannot be concluded
which of the upstream kinases are directly regulated by selective
regulation of PDE isoenzymes. Nevertheless, because the IKK signalsome
(Mercurio et al., 1997; Zandi et al., 1997
; Makarov, 2000
) is involved
in regulating I
B-
phosphorylation in response to various stimuli, including LPS, it remains tempting to suggest that this complex is
likely to form a target of the selective regulation by PDEs. Furthermore, whether this differential regulation of I
B-
phosphorylation/degradation is cAMP/cGMP-dependent cannot be confirmed
based on the aforementioned observations alone; however, because PDE
inhibitors are involved in regulating the dynamic equilibrium of these
cyclic nucleotides, the possibility that LPS-mediated I
B-
phosphorylation is cAMP/cGMP-sensitive cannot be excluded, an
observation correlating with the transcriptional activity of either
nucleotide (Montminy, 1997
; Zhong et al., 1997
; Ma et al., 1999
).
In association with targeting the I
B-
signaling pathway, we
observed differential regulation of NF-
B translocation and activation. Despite the observation that selective inhibition of PDEs
1, 3, and 4 exhibited no inhibitory effect on LPS-mediated translocation of NF-
B subunits, blockading the activity of 5, 6, and
9 differentially attenuated, and to relatively variable degree,
LPS-dependent translocation of these subunits. Because the latter
isoenzymes are directly involved in cGMP signaling, it is possible that
cAMP-mediated signaling tends to up-regulate NF-
B nuclear
accumulation, whereas the former pathway mediates an inhibitory effect,
thereby retarding the nuclear localization of selective subunits. This
discrepancy between the modes of action of either pathway suggested
that there is a line of demarcation highlighting the divergence of
these signaling mechanisms, especially on the bifurcation of interest
that substantially resides within and/or above the I
B/NF-
B
complex. Substantially working with effectiveness as competitive as
selective inhibition of PDEs 5, 6, and 9, pentoxifylline reduced
LPS-mediated NF-
B translocation, suggesting the involvement of a
common signaling pathway converging on NF-
B.
Analysis of this differential regulation of NF-
B subunit
translocation revealed the involvement of a novel biphasic pathway mediating the interference in NF-
B activation. Although selective inhibition of PDEs 1, 3, and 4 had a mild tendency to up-regulate the
activation of this transcription factor, ostensibly due to accumulation
of intracellular cAMP, selective inhibition of PDEs 5, 6, and 9 (
cGMP), along with pentoxifylline, negatively regulated LPS-mediated
NF-
B activation. This phenomenon is rather reinforced by the
observation that the molecular mechanism of inhibition by cAMP was
found to correlate with NF-
B, in particular, the RelA component of
the complex (Neuman et al., 1995
). Based on their chemical structures,
PDE inhibitors (1, 3, and 4 versus 5, 6, and 9) tend to elevate
cAMP/cGMP, respectively; however, it may also be true that in some
situations this may not be the only mode of action. In preference to
this understanding, some of the effects of PDE inhibition, for example,
may be implicated in regulating the process of cellular
differentiation, an effect not mimicked by cAMP (Yang et al., 1995
).
Furthermore, exogenous addition of TNF-
in the presence of rolipram,
purported to elevate intracellular cAMP, restored NF-
B activation
but not that of NFAT (Navarro et al., 1998
). Of note, a possible
relationship of pentoxifylline to Ca2+
mobilization has been declared because optimal c-Rel induction has been
shown to require the dual signal of phorbol-12-myristate-13-acetate and
ionomycin, where it was inferred that this nonselective PDE inhibitor
would blockade c-Rel induction by attenuating a component of the
calcium response (Yang et al., 1995
). From the aforementioned mechanisms reported, it is not clear, however, whether PDE inhibition is involved in regulating selective NF-
B subunits in correlation with the suppression or augmentation of transcriptional activation. This investigation has created a basis for the hypothesis claiming that
selective PDE blockade differentially regulate NF-
B
translocation/activation, with detailed mechanics of action on certain
subunits, where we have shown that not only c-Rel or RelA are targets
for the mode of action of PDEs but also other components of the complex
along with the machinery of I
B signaling that converge on regulating the NF-
B pathway. Despite the selective regulation of specific NF-
B subunit translocation/activation by PDE isoenzymes reported in
this study, whether the mode of action is solely cAMP/cGMP-sensitive cannot be inferred. However, previous studies in our laboratory have
demonstrated that cyclic nucleotides and their mimetics (forskolin, dibutyryl cAMP, and dibutyryl cGMP) have differentially
regulated proinflammatory cytokine biosynthesis, a phenomenon shown to
be correlated with the selective interference of NF-
B translocation and activation (J. J. Haddad, N. E. Saadé, B. Safieh-Garabedian, and S. C. Land, unpublished observations).
We herein report a novel immunopharmacological potential of selective
and nonselective PDE inhibition in the process of regulating the
I
B-
/NF-
B signaling transduction pathway. The results could be
highlighted as follows: 1) PDE blockade at the level of the diverging
cAMP/cGMP pathways differentially regulated the phosphorylation and
degradation of I
B-
, the major cytosolic inhibitor of NF-
B; 2)
inhibition of PDEs 1, 3, and 4 exhibited a tendency to augment the
process of selective NF-
B subunit translocation, an effect associated with up-regulating transcriptional activity; and 3) blockading the activity of PDEs 5, 6, and 9 negatively attenuated LPS-mediated NF-
B translocation/activation. It is concluded that selective and nonselective interference with the control of the dynamic
equilibrium of cyclic nucleotides via PDE isoenzyme regulation represents an immunopharmacological approach targeting the
I
B-
/NF-
B complex and the downstream signaling pathway, thereby
conferring a novel mode of action for targeting a transcriptional
activity notoriously implicated in regulating the progression of the
inflammatory process and its contraction in disease.
| |
Footnotes |
|---|
Accepted for publication October 19, 2001.
Received for publication July 27, 2001.
This study was supported by grants from Medical Research Council, Anonymous Trust, and Tenovus-Scotland (to S.C.L.), and R.L. allocated grants for supporting this research. J.J.H. holds the Georges John Livanos prize (London). Parts of this work were presented at Experimental Biology meeting; 2001 March 31-April 4; Orlando, FL.
Address correspondence to: Dr. John J. Haddad, Neuroscience Research Laboratory, Department of Anesthesia and Perioperative Care, University of California Medical Center, San Francisco, CA 94143. E-mail: jhaddad{at}itsa.ucsf.edu
| |
Abbreviations |
|---|
NF-
B, nuclear factor-
B;
I
B, inhibitory-
B;
LPS, lipopolysaccharide-endotoxin;
NLS, nuclear
localization sequence;
PDE, phosphodiesterase;
PKAc, catalytic subunit
of protein kinase A;
PDEI, phosphodiesterase inhibitor;
MBMQ, 4-{[3',4'-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline;
8-methoxymethyl-IBMX, 8-methoxymethyl-3-isobutyl-1-methylxanthine;
IKK, I
B kinase;
NFAT, nuclear factor of activated T cells.
| |
References |
|---|
|
|
|---|
B and I
B proteins: new discoveries and insights.
Annu Rev Immunol
14:
649-681[CrossRef][Medline].
B and human disease.
J Clin Invest
107:
3-6[CrossRef][Medline].
and NF-
B in perinatal lung epithelium requires glutathione biosynthesis.
Am J Physiol Lung Cell Mol Physiol
278:
L492-L503
B (RelA)-selective targeting.
Biochem Biophys Res Commun
271:
257-267[CrossRef][Medline].
-Melanocyte-related tripeptide, Lys-D-Pro-Val, ameliorates endotoxin-induced nuclear factor
B translocation and activation: evidence for involvement of an interleukin-1
193-195 receptor antagonism in the alveolar epithelium.
Biochem J
355:
29-38[CrossRef][Medline].
and NF-
B redox sensitivity evidence for inhibition by glutathione oxidation in alveolar epithelial cells.
J Biol Chem
275:
21130-21139
pO2/ROS) dependent release of IL-1
, IL-6 and TNF-
: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium.
Cytokine
13:
138-147[CrossRef][Medline].
B targeting in the alveolar epithelium.
Br J Pharmacol
133:
49-60[CrossRef][Medline].
B as a therapeutic target in chronic inflammation: recent advances.
Mol Med Today
6:
441-448[CrossRef][Medline].
B: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
Life Sci
67:
2513-2519[CrossRef][Medline].
B.
Curr Opin Cell Biol
11:
226-232[CrossRef][Medline].
B and NFAT.
J Virol
72:
4712-4720
B family friend and foe.
Trends Pharmacol Sci
25:
434-440.
B A key role in inflammatory disease.
J Clin Invest
107:
7-11[CrossRef][Medline].
B.
Annu Rev Cell Biol
10:
405-455[CrossRef].
B translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone and theophylline.
Naunyn-Schmiedeberg's Arch Pharmacol
359:
249-255[CrossRef][Medline].
B pathway in the treatment of inflammation and cancer.
J Clin Invest
107:
135-142[Medline].
-mediated neuroblastoma cell differentiation: modulation of calcium mobilization but not cAMP.
Biochem Biophys Res Commun
211:
1006-1014[CrossRef][Medline].
B kinase complex (IKK) contains two kinase subunits, IKK
and IKK
, necessary for I
B phoshorylation and NF-
B activation.
Cell
91:
243-252[CrossRef][Medline].
B is regulated by the I
B-associated PKAc subunit through a cyclic AMP-independent mechanism.
Cell
89:
413-424[CrossRef][Medline].
This article has been cited by other articles:
![]() |
H. J. Kwak, J. S. Song, J. Y. Heo, S. D. Yang, J.-Y. Nam, and H. G. Cheon Roflumilast Inhibits Lipopolysaccharide-Induced Inflammatory Mediators via Suppression of Nuclear Factor-{kappa}B, p38 Mitogen-Activated Protein Kinase, and c-Jun NH2-Terminal Kinase Activation J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1188 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Kumar, C. Herbert, P. S. Thomas, L. Wollin, R. Beume, M. Yang, D. C. Webb, and P. S. Foster Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 349 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dazert, K. Meissner, S. Vogelgesang, B. Heydrich, L. Eckel, M. Bohm, R. Warzok, R. Kerb, U. Brinkmann, E. Schaeffeler, et al. Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human Heart Am. J. Pathol., October 1, 2003; 163(4): 1567 - 1577. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||